-
公开(公告)号:KR101915973B1
公开(公告)日:2018-11-07
申请号:KR1020120065929
申请日:2012-06-20
Applicant: (주)아모레퍼시픽
Abstract: 본발명은자외선차단용유무기복합분체및 이를함유하는화장료조성물에관한것으로서, 보다자세하게는무기분체의표면을인지질로처리하여자외선차단능과분산성이향상된유무기복합분체및 상기복합분체를함유하여피부에도포시사용감및 보습력이개선된화장료조성물에관한것이다.
-
公开(公告)号:KR101914161B1
公开(公告)日:2018-11-02
申请号:KR1020137005744
申请日:2011-08-31
Applicant: (주)아모레퍼시픽
IPC: C07D487/04 , C07D403/04 , A61K31/519 , A61P29/00
CPC classification number: C07D487/04 , A61K31/519
Abstract: 본발명은카나비노이드 1 수용체저해제로작용하는신규화합물, 이의프로드럭, 이의약학적으로허용가능한염, 이의수화물또는이의용매화물을개시한다. 상기신규화합물등은카나비노이드 1 수용체매개질환의예방또는치료용으로유용하다.
-
公开(公告)号:KR101807619B1
公开(公告)日:2017-12-11
申请号:KR1020170009868
申请日:2017-01-20
Applicant: (주)아모레퍼시픽
IPC: A61K36/48 , A23L33/105 , A23L2/52
CPC classification number: A61K36/48 , A23L2/52 , A23L33/105 , A61K2236/333
Abstract: 본발명은저농도저급알코올로추출한콩 추출물또는그 분획물을함유하는조성물에관한것이다. 상기조성물은혈액순환개선효과가우수하고, 비만상태를개선시키며, 당뇨및 고질혈증등의예방, 증상의완화또는치료에효과적이다.
Abstract translation: 本发明涉及用低浓度低级醇提取的大豆提取物或含有该级分的组合物。 该组合物在改善血液循环,改善肥胖症,预防糖尿病和高脂血症以及缓解或治疗症状方面优异。
-
公开(公告)号:KR101604053B1
公开(公告)日:2016-03-16
申请号:KR1020110078309
申请日:2011-08-05
Applicant: (주)아모레퍼시픽
IPC: C07C235/46 , C07C235/48 , A61K8/42 , A61Q19/02
CPC classification number: A61K8/42 , A61Q19/00 , A61Q19/02 , C07C235/46 , C07C235/48 , C07C2603/74
Abstract: 본발명은신규벤조산아미드유도체화합물, 이의이성질체, 이의약학적으로허용가능한염, 이의프로드럭, 이의수화물또는이의용매화물을개시한다. 상기신규화합물등은뛰어난피부미백효과를가진다.
Abstract translation: 本发明公开了一种新的苯甲酸酰胺衍生物化合物,其异构体,其药学上可接受的盐,其前药,其水合物或其溶剂化物。 新化合物等具有优异的皮肤美白效果。
-
公开(公告)号:KR1020160026678A
公开(公告)日:2016-03-09
申请号:KR1020150108849
申请日:2015-07-31
Applicant: (주)아모레퍼시픽
IPC: C07C233/59 , A61K31/167 , A61K8/42 , A61K8/44
CPC classification number: C07C13/615 , A61K8/42 , A61K8/49 , A61K8/4973 , A61K31/166 , A61K31/167 , A61Q7/00 , A61Q19/008 , C07C15/04 , C07C231/02 , C07C233/57 , C07C233/58 , C07C233/59 , C07C233/60 , C07C233/63 , C07C265/12 , C07C2603/74
Abstract: 본발명은신규아다만탄유도체화합물, 이의이성질체, 이의약학적으로허용가능한염, 이의프로드럭, 이의수화물또는이의용매화물을개시한다. 또한, 상기신규아다만탄유도체화합물, 이의이성질체, 이의약학적으로허용가능한염, 이의프로드럭, 이의수화물또는이의용매화물의제조방법을개시한다. 상기신규아다만탄유도체화합물등은뛰어난안드로겐저해효과를가진다.
Abstract translation: 本发明公开了一种新型金刚烷衍生物; 其异构体; 其药学上可接受的盐; 其前药; 其水合物; 或其溶剂合物。 此外,公开了生产新型金刚烷衍生物化合物,其异构体,其药学上可接受的盐,其前药,其水合物或其溶剂合物的方法。 新颖的金刚烷衍生物化合物等具有优异的雄激素抑制作用。
-
公开(公告)号:KR1020140070474A
公开(公告)日:2014-06-10
申请号:KR1020130147705
申请日:2013-11-29
Applicant: (주)아모레퍼시픽
IPC: C07C235/08 , A61K31/164 , A61P17/16
CPC classification number: A61K8/42 , A61K8/68 , A61K2800/40 , A61Q19/007 , C07C233/18 , C07C235/08 , C07C235/28
Abstract: The present invention provides a novel pseudo-ceramide compound represented by Chemical Formula 1, an isomer, a pharmaceutically allowable salt, a pro-drug, a hydroxide, or a solvated compound thereof. [Chemical Formula 1] (In Chemical Formula 1, R1 and R2 are independently non-substituted or hydroxyl group-substituted C 9 to 23 saturated or unsaturated aliphatic chains.) According to the present invention, the compound has excellent stability and dissolubility and is effective in moisturizing the skin so as to protect the skin from external stimuli without side effects and be used as an active ingredient for recovering damaged skin and preventing skin damage. Accordingly, the compound can be used as an external skin application composition for moisturizing the skin, as a cosmetic composition, or as a pharmaceutical composition.
Abstract translation: 本发明提供由化学式1表示的新型假神经酰胺化合物,异构体,药学上可允许的盐,前药,氢氧化物或溶剂化物。 [化学式1]
(在化学式1中,R1和R2分别为非 取代或羟基取代的C 9〜23饱和或不饱和脂肪链)根据本发明,该化合物具有优异的稳定性和溶解性,并且有效地保湿皮肤,从而保护皮肤免受外部刺激而没有副作用 并用作恢复受损皮肤并防止皮肤损伤的活性成分。 因此,该化合物可以用作皮肤保湿剂,化妆品组合物或作为药物组合物的外用皮肤施用组合物。
-
公开(公告)号:KR1020130077953A
公开(公告)日:2013-07-10
申请号:KR1020110146636
申请日:2011-12-30
Applicant: (주)아모레퍼시픽
Abstract: PURPOSE: Carnosic acid, a derivative thereof, or a pharmaceutically acceptable salt thereof is provided to suppress elastase activation or matrix metalloproteinase-9 (MMP) expression, and to basically inhibit vital reaction mediated by the suppression. CONSTITUTION: An elastase activation inhibitor contains carnosic acid of chemical formula 1, a derivative thereof, or a pharmaceutically acceptable salt thereof as an active ingredient. The carnosic acid derivative is carnosic acid methyl ester or carnosic methyl alcohol. The carnosic acid, the derivative, or the pharmaceutically acceptable salt is derived from rosemary and/or sage. The inhibitor contains 0.0001-20 wt% of the active ingredient. An MMP expression inhibitor contains the carnosic acid, the derivative, or the pharmaceutically acceptable salt as an active ingredient. A composition for skin anti-aging contains the carnosic acid, the derivative, or the pharmaceutically acceptable salt as an active ingredient.
Abstract translation: 目的:为了抑制弹性蛋白酶活化或基质金属蛋白酶-9(MMP)的表达,基本上抑制由抑制介导的生物反应,提供鼠尾草衍生物或其药学上可接受的盐。 构成:弹性蛋白酶活化抑制剂含有化学式1的山梨酸,其衍生物或其药学上可接受的盐作为活性成分。 鼠尾草酸衍生物是鼠尾草酸甲酯或鼠尾草甲醇。 鼠尾草酸,衍生物或药学上可接受的盐衍生自迷迭香和/或鼠尾草。 抑制剂含有0.0001-20重量%的活性成分。 MMP表达抑制剂含有鼠尾草酸,衍生物或药学上可接受的盐作为活性成分。 用于皮肤抗衰老的组合物含有鼠尾草酸,衍生物或药学上可接受的盐作为活性成分。
-
公开(公告)号:KR1020130047555A
公开(公告)日:2013-05-08
申请号:KR1020120065929
申请日:2012-06-20
Applicant: (주)아모레퍼시픽
Abstract: PURPOSE: Organic and inorganic composite powder for blocking UV rays and a cosmetic composition containing the same are provided to ensure excellent UV protection ability, dispersion property, softness, and a moisturizing effect. CONSTITUTION: Organic and/or inorganic composite powder for blocking UV rays is prepared by surface-treating inorganic powder with one or more phospholipids selected from 2-methacryloyloxyethyl phosphorylcholine and 2-methacryloyloxyethyl phosphatidylcholine. The inorganic powder is selected among titanium oxide and zinc oxide. The inorganic powder contains 0.1-8% of phospholipid. A cosmetic composition for blocking UV rays contains 0.1-25wt% of organic and inorganic composite powder. [Reference numerals] (AA,CC) Absorbance(AU); (BB) Absorbance average value comparison at 310nm; (DD) Wavelength(nm)
Abstract translation: 目的:提供用于阻止紫外线的有机和无机复合粉末和含有它们的化妆品组合物,以确保优异的紫外线防护能力,分散性,柔软性和保湿效果。 构成:通过用选自2-甲基丙烯酰氧基乙基磷酰胆碱和2-甲基丙烯酰氧基乙基磷脂酰胆碱的一种或多种磷脂表面处理无机粉末制备用于阻断紫外线的有机和/或无机复合粉末。 无机粉末选自氧化钛和氧化锌。 无机粉末含有0.1-8%的磷脂。 用于阻挡紫外线的化妆品组合物含有0.1-25重量%的有机和无机复合粉末。 (标号)(AA,CC)吸光度(AU); (BB)310nm下的吸光度平均值比较; (DD)波长(nm)
-
公开(公告)号:KR100672183B1
公开(公告)日:2007-02-28
申请号:KR1020050078842
申请日:2005-08-26
Applicant: (주)아모레퍼시픽
Inventor: 서영거 , 오우택 , 김희두 , 이지우 , 박형근 , 박옥희 , 이용실 , 박영호 , 주영협 , 최진규 , 임경민 , 김선영 , 김진관 , 고현주 , 모주현 , 정연수 , 이정범 , 오영임
IPC: A61K31/17 , C07C335/04
CPC classification number: C07D333/42 , C07C311/08 , C07C311/47 , C07C333/20 , C07C335/12 , C07C335/14 , C07C335/20 , C07C335/26 , C07C2601/14 , C07C2602/10 , C07D207/323 , C07D207/416 , C07D207/42 , C07D209/08 , C07D209/14 , C07D213/40 , C07D213/61 , C07D213/76 , C07D217/06 , C07D231/14 , C07D231/56 , C07D233/64 , C07D235/14 , C07D239/42 , C07D241/12 , C07D241/24 , C07D277/28 , C07D295/13 , C07D295/215 , C07D295/32 , C07D307/52 , C07D311/58 , C07D317/58 , C07D333/20
Abstract: 본 발명은 바닐로이드 수용체(Vanilloid Receptor; VR)에 대한 조절제로서 신규한 티오우레아 유도체 및 이를 함유하는 약제학적 조성물에 관한 것이다.
바닐로이드 수용체의 활성과 연관된 질환에는 통증, 급성 통증, 만성 통증, 신경병적 통증, 수술후 통증, 편두통, 관절통, 신경병증, 신경손상, 당뇨병성 신경병, 신경변성 질환, 신경성 피부질환, 뇌졸중, 방광과민증, 과민성 장증후군, 천식과 만성폐색성 폐질환등 호흡기 이상, 피부, 눈, 점막의 자극, 발열, 위-십이지장궤양, 염증성 장 질환 및 염증성 질환 등이 포함될 수 있다. 본 발명은 이들 질환의 예방, 치료를 위한 약제학적 조성물을 제공한다.
바닐로이드 수용체, 티오우레아 유도체, 통증, 염증, 궤양 -
-
-
-
-
-
-
-
-